---
title: "Pfizer announces overall survival trial results for XTANDI targeting specific types of prostate canc"
description: "Pfizer announces overall survival trial results for XTANDI targeting specific types of prostate cancer"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261752375.md"
published_at: "2025-10-19T08:19:01.000Z"
---

# Pfizer announces overall survival trial results for XTANDI targeting specific types of prostate canc

> Pfizer announces overall survival trial results for XTANDI targeting specific types of prostate cancer

Pfizer announced the overall survival trial results of XTANDI for specific types of prostate cancer

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Basilea 将因其抗真菌药物从辉瑞获得 500 万美元的里程碑付款 | Basilea 将从辉瑞获得 500 万美元的里程碑付款，用于抗真菌药物 | [Link](https://longbridge.com/en/news/275275339.md) |
| 期权热点｜周二 PFE 跌 3%，部分看跌期权飙升 116% | 美东时间 02 月 03 日，辉瑞期权总成交 216437 张，看涨期权占比 59%，看跌期权占比 40%。 | [Link](https://longbridge.com/en/news/274753711.md) |
| Basilea Pharmaceutica 因在亚洲和中国的 Cresemba 销售获得了里程碑式的付款 | 巴西利亚制药公司（Basilea Pharmaceutica AG）宣布，由于其抗真菌药物 Cresemba（伊沙伏康唑）在亚太地区和中国的强劲销售，触发了一笔 500 万美元的里程碑付款，该药物通过其许可合作伙伴辉瑞（Pfizer）销售。 | [Link](https://longbridge.com/en/news/275271671.md) |
| 美股盘前热门交易：辉瑞盘前跌 3.56%；Coreweave 盘前涨 3.16% | 辉瑞盘前跌 3.56%；Coreweave 盘前涨 3.16%；Fatpipe 盘前涨 76.63%；Inlif 盘前涨 47.28%；Texxon 盘前涨 34.21%。 | [Link](https://longbridge.com/en/news/274658583.md) |
| 期权热点｜周三 PFE 涨 3%，部分看涨期权飙升 533% | 美东时间 02 月 04 日，辉瑞期权总成交 245077 张，看涨期权占比 76%，看跌期权占比 23%。 | [Link](https://longbridge.com/en/news/274912810.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.